The effective and safe treatment of pain is an unmet health-care need. Current medications
used for pain management are often only partially effective, carry dose-limiting adverse …

Voltage-gated sodium channels (VGSCs) are key mediators of intrinsic neuronal and muscle
excitability. Abnormal VGSC activity is central to the pathophysiology of epileptic seizures …

Impairments in cognition are common in epilepsy and may be caused or exacerbated by
antiseizure medications (ASMs). Positive effects on cognition may also be seen with some …

In the past twenty years, 14 new antiepileptic drugs have been approved for use in the
United States and/or Europe. These drugs are eslicarbazepine acetate, felbamate …

Purpose Despite many new ASM, the rate of patients with drug-resistant epilepsy (DRE) has
not changed. Cenobamate (CNB) is a novel ASM for the treatment of focal-onset seizures in …

Lacosamide was the first approved third-generation antiepileptic drug. However, real-world
data regarding its adverse cardiac reactions in large samples still need to be completed. We …

Lacosamide—a third-generation antiepileptic drug available in multiple formulations—was
first approved in 2008 as adjunctive therapy for partial-onset seizures (POS) in adults. In …

In the past twenty-one years, 17 new antiepileptic drugs have been approved for use in the
United States and/or Europe. These drugs are clobazam, ezogabine (retigabine) …

Abstract The Neuronal Ceroid Lipofuscinoses (NCLs) are a family of autosomal recessive
neurodegenerative disorders that annually affect 1: 100,000 live births worldwide. This …

Introduction: Treatment of pediatric epilepsy requires a careful evaluation of the safety and
tolerability profile of antiepileptic drugs (AEDs) to avoid or minimize as much as possible …